Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Seamlessly bridge your LNP discovery journey from RUO to bulk GLP-tox and GMP excipient-grade material.
Explore CGMP Lipid ServicesL-319 is an ionizable cationic (pKa = 6.38) and biodegradable lipid derivative of DLin-MC3-DMA (Item No. 34364) that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing L-319 and encapsulating siRNA encoding Factor VII (FVII) reduce serum levels of FVII in mice. LNPs containing L-319 in combination with cKK-E12 (Item No. 36700) and encapsulating varicella-zoster virus (VZV) mRNA encoding glycoprotein E (gE) increase the lymph node and spleen levels of CD11c+CD80+ and CD11c+CD86+ cells and total serum IgG titers in mice, as well as decrease the number of VZV-induced rashes and the epithelial levels of VZV DNA, in a guinea pig model of VZV-induced shingles.2
WARNING This product is not for human or veterinary use.
1. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21(8), 1570-1578 (2013).
2. A synergistic lipid nanoparticle encapsulating mRNA shingles vaccine induces potent immune responses and protects guinea pigs from viral challenges. Adv. Mat. 36(13), e2310886 (2023).